Page 6,610«..1020..6,6096,6106,6116,612..6,6206,630..»

Propecia Online Pharmacy Uk

Posted: Published on July 30th, 2012

Por FRANK GAUD CARRAU MAYAGEZ (AP) El representante por el distrito de Mayagez y San Germn, que en enero empez su tercer cuatrienio en la Cmara Baja, dijo que comenzar a evaluar su futuro poltico, en el que no descarta del todo aspirar a otro puesto electivo. "Ser el tiempo el que se encargar de definir mi futuro poltico o profesional, pero seguir confrontando a quienes deseen llevar a mi partido y a Puerto Rico por caminos de inmovilismo y sumisin", manifest el legislador en conferencia de prensa al recordar que haba prometido que no optara por ms de tres trminos a una misma posicin. Aunque dej la puerta abierta a aspirar a otro cargo electivo, Hernndez rechaz rotundamente que interese ocupar la alcalda mayagezana. Asimismo, afirm que continuar luchando por que el PPD "se mueva a mejorar un ELA soberano". Durante los pasados meses, Hernndez y otras figuras populares han confrontado al liderato del PPD y a la Comisin de Asuntos Federales de esa colectividad creada para discutir el asunto del estatus por las marcadas diferencias entre ambos respecto a la direccin que debe tomar el partido en torno a la definicin poltica de Puerto Rico. El debate se … Continue reading

Posted in Online Pharmacy | Comments Off on Propecia Online Pharmacy Uk

O.C. health firm sells pharmacy division

Posted: Published on July 30th, 2012

O.C. health firm sells pharmacy division July 30th, 2012, 9:30 am posted by Jan Norman, small-business columnist A-Med Health Care in Huntington Beach has sold its specialty pharmacy division to Altamont Capital Partners, a Palo Alto private equity firm. Altamont is creating a new company, called ModernHEALTH Specialty Pharmacy, which will combine A-Meds assets and the specialty pharmacy operations of Modern HEALTHcare Inc. in Monrovia. Terms of the deals were not disclosed. In a letter to customers, A-Med Health Care CEO Larry Thacker said, Going forward, A-Med will continue to service its medical supply and enteral nutrition patients and health care providers, as well as maintain its industry leading position as the premier medical supply provider in California. The new ModernHEALTH Specialty will be based in Monrovia and serve the needs of patients in 15 states. The company will focus on specialty infusion, particularly IVIG therapy, as well as specialty pharmaceutical therapies with high service needs such as HIV, cystic fibrosis, transplants, hepatitis C and multiple sclerosis. Richard Katz, CEO of ModernHEALTH Specialty Pharmacy, Over the years we have built a substantial specialty pharmacy business at Modern including BioFusion, a leader in the specialty infusion market. Continuing to build these … Continue reading

Posted in Pharmacy | Comments Off on O.C. health firm sells pharmacy division

CVS/pharmacy's "Project Health" Bringing Free Health Screenings to 10 Cities During August

Posted: Published on July 30th, 2012

WOONSOCKET, R.I., July 30, 2012 /PRNewswire/ -- Throughout the month of August, which is National Immunization Awareness Month, CVS/pharmacy's Project Health ("Proyecto Salud" in Spanish) is offering free health screening events focusing on vaccination reviews, vision acuity, glucose, blood pressure and BMI (Body Mass Index) for individuals in multicultural communities who have difficulty accessing preventive care. (Logo: http://photos.prnewswire.com/prnh/20100816/NE50800LOGO ) (Logo: http://photos.prnewswire.com/prnh/20120207/NE48106LOGO-a ) Along with these free health screening events, CVS/pharmacy designated Project Health store locations are also holding "Flu Voucher Fridays" each week during the month of August. Qualifying Project Health attendees who complete the entire health screening process and identify themselves as not having health insurance will be eligible to receive a voucher redeemable for a flu shot at CVS/pharmacy or MinuteClinic this flu season. More than 200 Project Health events will take place during the month of August in the following cities: Atlanta, Chicago, Dallas-Fort Worth, Detroit, Houston, Los Angeles, Miami, New York City, Philadelphia and Washington, D.C. Parents are encouraged to bring their children's immunization records to the events in preparation for school. Although children age seven and older can participate in only two screenings vaccination reviews and vision acuity they are eligible to qualify to receive … Continue reading

Posted in Pharmacy | Comments Off on CVS/pharmacy's "Project Health" Bringing Free Health Screenings to 10 Cities During August

CVS/pharmacy and MinuteClinic Launch Flu Shot Voucher Program for Patients in Need This Flu Season

Posted: Published on July 30th, 2012

WOONSOCKET, R.I., July 30, 2012 /PRNewswire/ -- CVS/pharmacy and MinuteClinic will support people in need this flu season through a flu shot voucher program being held in August as part of CVS/pharmacy's Project Health free screening events. Qualifying patients who attend a "Flu Voucher Fridays" Project Health event, complete the screenings, and identify themselves as not having health insurance will receive a voucher redeemable for a flu shot at any CVS/pharmacy or MinuteClinic location this flu season. (Logo: http://photos.prnewswire.com/prnh/20100816/NE50800LOGO ) The flu shot vouchers are being offered as part of National Immunization Awareness Month. CVS/pharmacy's Project Health (Proyecto Salud in Spanish) is also offering free health screening events in August. Screenings will focus on vaccination reviews, vision acuity, glucose, blood pressure and Body Mass Index (BMI) for individuals in multicultural communities who have difficulty accessing preventive care. More than 200 Project Health events will take place in Atlanta, Chicago, Dallas-Fort Worth, Detroit, Houston, Los Angeles, Miami, New York City, Philadelphia and Washington, DC. "CVS/pharmacy and MinuteClinic are committed to being the most convenient place to get a flu shot this season," said Papatya Tankut, Vice President, Pharmacy Professional Services at CVS/pharmacy. "Offering flu shot vouchers to patients who may have … Continue reading

Posted in Pharmacy | Comments Off on CVS/pharmacy and MinuteClinic Launch Flu Shot Voucher Program for Patients in Need This Flu Season

CoramRx Specialty Pharmacy Services Receives URAC Specialty Pharmacy Accreditation

Posted: Published on July 30th, 2012

DENVER, July 30, 2012 (GLOBE NEWSWIRE) -- CoramRx Specialty Pharmacy Services announced today that it has been awarded Specialty Pharmacy Accreditation from URAC, a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry. URAC's Specialty Pharmacy Accreditation ensures that organizations meeting the rigors of accreditation uphold the highest standards in the industry, and reinforces the best clinical and organizational practices for ensuring appropriate and safe medication use and optimal patient outcomes. "The growth of CoramRx's customer base in the managed care and prescription benefit manager community led to the need to seek a second accreditation for the business," said Lori Jordon, Director of Operations for CoramRx. "What makes URAC unique is its focus on and standardization of the quality improvement process and ongoing reporting of performance metrics for organizations seeking accreditation." CoramRx offers national distribution and local services through specialty pharmacy facilities, more than 85 infusion pharmacies, and over 65 ambulatory infusion suites across the United States. With more than 30 years of industry experience, clinical knowledge, and dedicated pharmacy teams, it ensures optimal access to all types of specialty products including oral, injectable, and infusible medications. CoramRx is an affiliate of Coram Specialty … Continue reading

Posted in Pharmacy | Comments Off on CoramRx Specialty Pharmacy Services Receives URAC Specialty Pharmacy Accreditation

Osiris Therapeutics falls as Sanofi tiff continues

Posted: Published on July 30th, 2012

NEW YORK (AP) -- Shares of Osiris Therapeutics Inc. fell Monday as the company said it is still negotiating with French drugmaker Sanofi about the rights to its stem cell therapy Prochymal. Osiris President and CEO Randal Mills said his company's dispute with Sanofi is "in the hands of lawyers" and that Osiris and Sanofi are trying to amicably resolve their disagreements over the status of Prochymal. The therapy is a treatment for graft vs. host disease, a condition in which transplanted bone marrow cells attack the body of the patient. The Columbia, Md., company was developing Prochymal through a partnership with biotechnology company Genzyme. French drugmaker Sanofi later acquired Genzyme, and in February, Sanofi said it discontinued late-stage testing of Prochymal. Osiris said that means the collaboration is over and it should regain the rights to Prochymal, allowing it to market the drug or find another partner. Sanofi disagrees. Shares of Osiris Therapeutics fell 95 cents, or 9.5 percent, to $9.08 in afternoon trading. Canadian regulators granted conditional approval to Prochymal in May, and regulators in New Zealand gave full approval to Prochymal in June. In a conference call, Osiris said it expects Prochymal to be available in Canada … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Osiris Therapeutics falls as Sanofi tiff continues

Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Posted: Published on July 30th, 2012

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012. Highlights and Recent Developments This past quarter was not only memorable, but monumental, for Osiris, stated C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics. We have set a new benchmark to measure our success, and remain as committed as ever to extending the reach of this remarkable technology. Whether through our Biosurgery or Therapeutics units, we will continue to develop innovative cell therapy solutions for patients in need. Second Quarter Financial Results Biosurgery product revenue rose 43% from the previous quarter to $1.63 million. As of June 30, 2012, Osiris had $40.1 million of cash, receivables and short-term investments. Research and development expenses for the second quarter of 2012 were $4.1 million, compared to $5.2 million incurred in the second quarter of 2011. General and administrative (G&A) expenses were $1.4 million for the second quarter of 2012 compared to $3.3 million for the same period of the prior year. The 2011 G&A expense included … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Osiris Therapeutics falls as Sanofi tiff continues

Posted: Published on July 30th, 2012

NEW YORK (AP) -- Shares of Osiris Therapeutics Inc. fell Monday as the company said it is still negotiating with French drugmaker Sanofi about the rights to its stem cell therapy Prochymal. Osiris President and CEO Randal Mills said his company's dispute with Sanofi is "in the hands of lawyers" and that Osiris and Sanofi are trying to amicably resolve their disagreements over the status of Prochymal. The therapy is a treatment for graft vs. host disease, a condition in which transplanted bone marrow cells attack the body of the patient. The Columbia, Md., company was developing Prochymal through a partnership with biotechnology company Genzyme. French drugmaker Sanofi later acquired Genzyme, and in February, Sanofi said it discontinued late-stage testing of Prochymal. Osiris said that means the collaboration is over and it should regain the rights to Prochymal, allowing it to market the drug or find another partner. Sanofi disagrees. Shares of Osiris Therapeutics fell 95 cents, or 9.5 percent, to $9.08 in afternoon trading. Canadian regulators granted conditional approval to Prochymal in May, and regulators in New Zealand gave full approval to Prochymal in June. In a conference call, Osiris said it expects Prochymal to be available in Canada … Continue reading

Comments Off on Osiris Therapeutics falls as Sanofi tiff continues

Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Posted: Published on July 30th, 2012

COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc. (OSIR), the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today its results for the second quarter ended June 30, 2012. Highlights and Recent Developments This past quarter was not only memorable, but monumental, for Osiris, stated C. Randal Mills, Ph.D., President and Chief Executive Officer of Osiris Therapeutics. We have set a new benchmark to measure our success, and remain as committed as ever to extending the reach of this remarkable technology. Whether through our Biosurgery or Therapeutics units, we will continue to develop innovative cell therapy solutions for patients in need. Second Quarter Financial Results Biosurgery product revenue rose 43% from the previous quarter to $1.63 million. As of June 30, 2012, Osiris had $40.1 million of cash, receivables and short-term investments. Research and development expenses for the second quarter of 2012 were $4.1 million, compared to $5.2 million incurred in the second quarter of 2011. General and administrative (G&A) expenses were $1.4 million for the second quarter of 2012 compared to $3.3 million for the same period of the prior year. The 2011 G&A expense included … Continue reading

Comments Off on Osiris Therapeutics Reports Second Quarter 2012 Financial Results

Cayden's second chance: 5-year-old has stem cell injection that may help his vision

Posted: Published on July 30th, 2012

The quest to save her grandson's eyesight began more than four years ago when Carmie Carr discovered a business on the Internet offering experimental stem cell injections in China. At 4 months old, Cayden Baggett was diagnosed with optic nerve hypoplasia, a condition where the nerves in the eyes never fully develop. His family was told he would eventually go blind. Right now, Cayden can see light and dark, but little else. Soon after learning about the stem cell treatments, the Carr family launched a campaign to raise $50,000 to cover the costs. The 2010 Gulf oil spill, coupled with the 2011 tornadoes in Tuscaloosa that destroyed their retail business, made collecting the funds next to impossible, they said. Then, a friend told the family about a construction project he was working on just down the street. It was for a local radiologist who planned to offer stem cell injections to athletes with sports-related injuries. He introduced the Carrs to Dr. Jason Williams. After talking with the family and researching the procedures, Williams agreed to help. "There is no doubt in my mind this is the road the Lord has been leading us down," said Carmie Carr. "It connected like … Continue reading

Comments Off on Cayden's second chance: 5-year-old has stem cell injection that may help his vision

Page 6,610«..1020..6,6096,6106,6116,612..6,6206,630..»